PDS Biotech Reports Third Quarter 2026 Financial Results
PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PDS Biotech Reports Third Quarter 2026 Financial Results PRINCETON, N.J., November 13, 2026 -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company focused on transforming how the immune system targets
How this was made
The 30-second read
Why it matters
The filing provides the first public view of Q3 2026 results and a fresh capital raise, offering traders fresh data to price the stock.
Market read
The results and financing are material for PDSB's valuation and may influence micro‑cap biotech sentiment.
What to watch
The new patents in Japan, India and Israel broaden IP protection, which may enhance future partnership valuations.
PDS Biotech cuts quarterly R&D and operating expenses, narrows net loss to $7.6 million, and reports $15.2 million in cash at September 30, 2026
Quarterly operating expenses and net loss fell year over year, with R&D down $2.5 million. Cash fell from $26.7 million at December 31, 2025 to $15.2 million at September 30, 2026, net interest expense rose to $1.7 million, the filing names a going concern risk, and no guidance was issued.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net loss, three months ended September 30, 2026GAAP | $7.6M | – | – |
| Net loss per share, basic and diluted, three months ended September 30, 2026GAAP | $0.11 | – | – |
| Research and development expenses, three months ended September 30, 2026GAAP | $2.1M | – | decrease of $2.5 million |
| General and administrative expenses, three months ended September 30, 2026GAAP | $3.8M | – | increase of $0.2 million |
| Total operating expenses, three months ended September 30, 2026GAAP | $5.9M | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | $(5,896,104) | – | – |
| Interest income, three months ended September 30, 2026GAAP | $41,630 | – | – |
| Interest expense, three months ended September 30, 2026GAAP | $(1,766,451) | – | – |
| Net interest income (expense), three months ended September 30, 2026GAAP | $1.7 million net interest expense | – | – |
| Benefit from income taxes, three months ended September 30, 2026GAAP | - | – | – |
| Research and development expenses, nine months ended September 30, 2026GAAP | $8,773,832 | – | – |
| General and administrative expenses, nine months ended September 30, 2026GAAP | $10,140,094 | – | – |
| Total operating expenses, nine months ended September 30, 2026GAAP | $18,913,926 | – | – |
| Interest income (expense), net, nine months ended September 30, 2026GAAP | $(5,806,630) | – | – |
| Loss before income taxes, nine months ended September 30, 2026GAAP | $(24,720,556) | – | – |
| Benefit from income taxes, nine months ended September 30, 2026GAAP | - | – | – |
| Net loss, nine months ended September 30, 2026GAAP | $(24,720,556) | – | – |
| Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP | $(0.40) | – | – |
| Cash and cash equivalents at September 30, 2026GAAP | $15.2M | – | – |
| Total assets at September 30, 2026GAAP | $18,571,942 | – | – |
| Total stockholders' equity at September 30, 2026GAAP | $13,495,140 | – | – |
Capital returns
- No share repurchases or dividends are reported in the filing.
- The company announced the initial closing of a PIPE financing of up to $22.3 million led by Nant Capital, LLC with additional participation from current investors. The filing says the initial closing was completed this quarter but does not state the amount of that initial closing.
- The PIPE includes a contingent milestone closing triggered by the Company's submission to the FDA of a registrational Phase 3 clinical trial protocol for PDS0301, subject to the satisfaction or waiver of applicable closing conditions.
- In connection with the PIPE, the Company entered into an option agreement granting NantWorks, LLC a one-year exclusive right to negotiate an exclusive license for the PDS0101 program.
What drove it
- The company attributes the R&D decrease of $2.5 million primarily to decreases of $1.6 million in clinical trial costs, $0.6 million in personnel costs and $0.3 million in manufacturing costs.
- The company attributes the G&A increase of $0.2 million primarily to an increase of $0.3 million in professional fees and an increase of $0.1 million in personnel costs, offset by a decrease of $0.2 million in stock based compensation costs.
- Net interest expense was $1.7 million for the quarter versus $0.9 million a year earlier. Gross interest expense was $1,766,451 versus $1,150,378, and interest income was $41,630 versus $281,109. The filing does not give a reason for these changes.
- Net loss for the nine months was $(24,720,556) versus $(26,932,586). The prior-year nine-month period included a benefit from income taxes of $1,169,820, which the current period does not show.
Concerns
- Cash and cash equivalents fell from $26,711,969 at December 31, 2025 to $15,245,081 at September 30, 2026.
- The forward-looking statements list the company's ability to continue as a going concern and its dependence on additional financing as risk factors.
- Net interest expense increased to $1.7 million from $0.9 million, and gross interest expense increased to $1,766,451 from $1,150,378.
- Long-term debt was $11,733,350 at December 31, 2025 and is shown as '-' at September 30, 2026. The filing does not explain the change.
- Weighted average shares outstanding rose to 71,936,955 for the quarter from 46,869,531 a year earlier, which increases the dilution base for per-share results.
- The forward-looking statements list the company's ability to regain and maintain compliance with Nasdaq continued listing requirements, including the minimum bid price requirement, and the risk of delisting.
What to watch
- Closing of the PIPE financing: the amount of the initial closing and the timing and conditions of the contingent milestone closing tied to submission of a registrational Phase 3 protocol for PDS0301 to the FDA.
- Cash runway: cash of $15,245,081 at September 30, 2026 against quarterly net loss of $7.6 million and net interest expense of $1.7 million.
- The one-year NantWorks option to negotiate an exclusive license for PDS0101, and the company's stated intent to pursue strategic partnerships or other externally funded opportunities for PDS0101 Phase 3 development.
- The status of the going concern language and the Nasdaq minimum bid price requirement.
- Clinical progress for PDS0301 at the NCI and in the Phase 2 trials discussed at the KOL event.
- Interest expense trend, given the change from $1,150,378 to $1,766,451 and the removal of long-term debt from the balance sheet.
Balance sheet and cash flow
- Cash and cash equivalents: $15,245,081 at September 30, 2026 versus $26,711,969 at December 31, 2025.
- Working capital: $13,297,920 at September 30, 2026 versus $18,770,871 at December 31, 2025.
- Total assets: $18,571,942 at September 30, 2026 versus $30,494,083 at December 31, 2025.
- Long-term debt: none at September 30, 2026 (printed as '-') versus $11,733,350 at December 31, 2025. The filing does not state how this balance was settled or reclassified.
- Accumulated deficit: $(241,327,060) at September 30, 2026 versus $(216,606,504) at December 31, 2025.
- Total stockholders' equity: $13,495,140 at September 30, 2026 versus $9,251,833 at December 31, 2025.
- Weighted average common shares outstanding, basic and diluted: 71,936,955 for the three months ended September 30, 2026 versus 46,869,531 for the same period of 2025. For the nine months: 61,145,055 versus 44,648,508.
- The filing contains no operating cash flow, investing cash flow or free cash flow figures.
Analysis
PDS Biotech reported a third-quarter 2026 net loss of $7.6 million, or $0.11 per basic and diluted share, against $9.0 million, or $0.19 per share, a year earlier. The company's own explanation for the lower operating spend is in its R&D and G&A commentary. R&D fell to $2.1 million from $4.6 million, a decrease of $2.5 million, which the filing primarily attributes to lower clinical trial costs of $1.6 million, personnel costs of $0.6 million and manufacturing costs of $0.3 million. G&A rose to $3.8 million from $3.6 million, which the filing attributes mainly to higher professional fees of $0.3 million. Total operating expenses declined to $5.9 million from $8.1 million, and the nine-month figures show the same direction, with R&D at $8,773,832 against $14,620,308 and total operating expenses at $18,913,926 against $24,869,251.
Below the operating line, the quarter's result was pressured by financing costs. Net interest expense was $1.7 million against $0.9 million a year earlier, with gross interest expense of $1,766,451 against $1,150,378 and interest income of $41,630 against $281,109. The filing does not explain these changes. The nine-month net loss was $(24,720,556), narrower than $(26,932,586) in the prior-year period. That period included a tax benefit of $1,169,820, which the current period does not show, so the nine-month comparison is affected by that item as well as by the lower operating spend.
The balance sheet shows a weaker liquidity position. Cash and cash equivalents fell to $15,245,081 from $26,711,969 at December 31, 2025. Total assets declined to $18,571,942 from $30,494,083, and long-term debt of $11,733,350 at year-end 2025 is shown as '-' at September 30, 2026. Stockholders' equity rose to $13,495,140 from $9,251,833. The filing does not describe how the debt was settled or what funded the equity increase, though it does describe a PIPE financing of up to $22.3 million led by Nant Capital, LLC, whose initial closing was completed this quarter. The amount of that initial closing is not stated. The company's forward-looking statements name going concern risk, dependence on additional financing and Nasdaq minimum bid price compliance as risks.
The filing contains no revenue, segment, cash flow or forward guidance figures, so the read rests on the cost base, financing costs and balance sheet. Weighted average shares rose to 71,936,955 from 46,869,531 for the quarter, a figure that should be read alongside the per-share loss. The governance and pipeline items, including three new independent directors effective October 18, 2026, the NantWorks option on PDS0101 and the publication of VERSATILE-002 results, are reported as events and carry no financial figures in the filing.
Management, verbatim
During our third quarter, we continued to execute our strategic prioritization of PDS0301, our investigational tumor-targeted IL-12 immunocytokine, as our lead development program.
Frank Bedu-Addo, PhD, President and Chief Executive Officer, PDS Biotech
We believe the ongoing clinical trials of PDS0301 at the NCI, along with those of our cancer vaccine platform, support our view that targeted T cell immunotherapy has the potential to change how solid tumors are treated.
Frank Bedu-Addo, PhD, President and Chief Executive Officer, PDS Biotech
Not in the filing
stated, not guessed- Revenue: the filing reports no revenue line and no revenue figures.
- Gross margin and cost of sales: not reported.
- Guidance for any future period: not provided.
- Prior-quarter (June 30, 2026) comparatives: not printed.
- Percentage changes for net loss, operating expenses, interest expense and per-share loss: not printed.
- Balance sheet comparatives at September 30, 2025 for cash, total assets and stockholders' equity: not printed. Only December 31, 2025 comparatives appear and are shown in balance_sheet_cash_flow.
- Operating cash flow, investing cash flow, financing cash flow and free cash flow: not reported.
- Amount of the initial closing of the PIPE financing: not stated (only the up-to $22.3 million total is printed).
- Reason for the disappearance of long-term debt from the balance sheet: not explained.
- Reason for the change in interest income and interest expense: not explained.
- Consensus estimates, analyst expectations and share price reaction: not in the documents.
- Segment data: the company reports a single business and no segment table.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
PDS Biotechnology Corp (Nasdaq: PDSB) is a clinical‑stage immunotherapy company focusing on IL‑12 immunocytokine and cancer vaccine platforms.
Ticker impact
The 8‑K filing discloses Q3 2026 financial results, a $22.3 M PIPE financing, new board appointments and patent issuances, all first reported here.
potential downside as net loss expands, partially offset by financing support and trial updates
Losses increased YoY, but the $22.3 M PIPE and exclusive license option to NantWorks provide near‑term liquidity and strategic upside.
Market effects
Biotech sector may see modest pressure as small‑cap earnings miss expectations, but financing activity could buoy peer funding sentiment.
U.S. biotech investors may adjust exposure to early‑stage immunotherapy firms.
Limited; the news is specific to a micro‑cap U.S. listed biotech.
Counterpoint
Despite the widened loss, the PIPE financing and exclusive license could enable a rapid clinical milestone, making the stock a potential rebound candidate.
Key entities
- InvestorNant Capital, LLC
Lead investor in the $22.3 M PIPE financing.
- Board MemberDr. Patrick Soon‑Shiong
Founder of NantWorks, appointed to the board as a designee of Nant Capital.


